This fall, the University of Pennsylvania’s Basser Research Center for BRCA is taking its lifesaving efforts to raise awareness about hereditary breast and ovarian cancers on the road and into synagogues across the country.

Eighty-three percent of cancer doctors report that they’ve faced oncology drug shortages, and of those, nearly all say that their patients’ treatment has been impacted, according to a study from researchers at the Abramson Cancer Center and the Perelman School of Medicine at the University of P

The kidney and liver cancer drug sorafenib holds metastatic thyroid cancer at bay for nearly twice as long as a placebo, according to results of a randomized phase III trial, which will be presented today by a researcher from the Abramson Cancer Center and the Perelman School of Medicine at the

In the largest clinical trial to date to examine the efficacy of PARP inhibitor therapy in BRCA 1/2 carriers with diseases other than breast and ovarian cancer, the oral drug olaparib was found to be effective against advanced pancreatic and prostate cancers.

A study led by researchers at the Perelman School of Medicine at the University of Pennsylvania and Boston University School of Medicine has found that nearly one quarter of patients may return to the emergency department within 30 days of being discharged from a hospitalization.

Though the toll of sepsis is known to be enormous – it is estimated to cost the U.S. health care system $24.3 billion each year, and is the nation’s third-leading killer, behind heart disease and cancer – the true magnitude of incidence of and death from the illness remains unknown.

Addressing on the challenges that accompany transitions between health care settings could be a key strategy for improving clinical outcomes for people living with HIV, according to researchers from the Perelman School of Medicine at the University of Pennsylvania.

The wide consensus that health care spending poses a threat to the nation’s fiscal solvency has led to the championing of “value” as a goal of health care reform efforts.

PHILADELPHIA — Most ovarian cancer patients are diagnosed with late stage disease that is unresponsive to existing therapies.

PHILADELPHIA — In the first study to examine discussion of drug side effects on Internet message boards, researchers from the Perelman School of Medicine at the University of Pennsylvania found that breast cancer survivors taking the commonly prescribed adjuvant therapy known as aromatase inhibitors (AIs) often detailed in these forums troublesome symptoms resulting from the drugs, and they we